AI Summary Symdeko (tezacaftor/ivacaftor) is a combination CFTR modulator for cystic fibrosis with eligible CFTR mutations and is not specifically approved to treat liver disease.
Medically reviewed.
Symdeko (tezacaftor/ivacaftor) is a prescription combination CFTR modulator. It treats cystic fibrosis (CF) in people with eligible CFTR gene mutations. It improves the amount and function of the defective CFTR protein, which helps chloride transport, lung function, and overall CF management. In people with cystic fibrosis–associated liver disease (CFLD), treating the underlying CFTR defect may also support liver health, but Symdeko is not specifically approved to treat liver disease. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Symdeko in CF care: how it works, who may be prescribed it, how it is used, benefits, side effects, and monitoring, including liver tests. You can also connect with a liver specialist near you for personalized guidance on your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT SYMDEKO TREATMENT
Symdeko is a prescription medicine that combines tezacaftor and ivacaftor. It belongs to a group of medicines called CFTR modulators. Doctors use it to treat cystic fibrosis (CF) in people with eligible CFTR gene mutations.
Symdeko improves the quantity and function of the defective CFTR protein. This helps improve chloride transport, lung function, and overall disease management.
People with CF may develop cystic fibrosis–associated liver disease (CFLD). In these patients, treating the underlying CFTR defect may also support liver health.
WHO SYMDEKO MAY BE SUITABLE FOR
Your healthcare provider may prescribe Symdeko if you have cystic fibrosis with an eligible CFTR mutation. Genetic testing confirms whether you are eligible for CFTR modulator therapy.
It may also be considered if you need long-term treatment to improve CFTR protein function, or if you have pulmonary (lung) manifestations of cystic fibrosis.
Your medical history, genetic test results, liver function, and other medications all factor into whether Symdeko is appropriate. Your provider may adjust the dose if you have liver impairment or take certain medications.
Because every patient's health profile is different, treatment decisions should be made by a qualified healthcare professional.
ELIGIBILITY OVERVIEW
Symdeko may be considered for people with the following conditions or treatment goals:
Before recommending Symdeko, healthcare providers evaluate several factors to decide whether it is appropriate, including:
HOW SYMDEKO CAN HELP
Symdeko combines two medicines that act on the CFTR protein. Tezacaftor improves how the defective CFTR protein is processed and moved to the cell surface. Ivacaftor helps the CFTR chloride channel open.
Together, they improve chloride and water transport across epithelial cells, the cells that line organs such as the lungs. This helps improve mucus hydration and clearance.
Symdeko addresses the underlying cause of cystic fibrosis rather than only treating symptoms. In people with CFLD, treating the underlying CFTR defect may also support liver health, although Symdeko is not approved for that purpose. Providers monitor response with regular checks, including Liver Function Tests (LFTs).
HOW SYMDEKO MAY HELP
In cystic fibrosis, the CFTR protein is defective. Symdeko combines two medicines that each act on this protein. Together they improve both the quantity and the function of the CFTR protein.
Two medicines, two jobs:
The CFTR protein helps move chloride and water across epithelial cells, the cells that line organs such as the lungs. When CFTR works better, chloride and water transport improves. This helps improve mucus hydration and clearance, so mucus is less likely to stay thick and hard to clear.
By improving CFTR function, Symdeko helps improve breathing and respiratory health in eligible people with CF, including those with lung (pulmonary) manifestations. It may also decrease pulmonary flare-ups and hospitalizations. Results vary from person to person, and Symdeko works best alongside routine CF care.
In people with CFLD, treating the underlying CFTR defect may also support liver health. Symdeko is not specifically approved to treat liver disease, so it does not replace liver care. Your provider will keep monitoring your liver function with regular tests while you take it.
Symdeko targets the underlying CFTR defect in cystic fibrosis. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Symdeko comes as oral tablets in two parts: a morning combination tablet (tezacaftor/ivacaftor) and an evening ivacaftor tablet. Check with your pharmacist if you have questions about your tablets.
Typical adult and eligible pediatric dosing is one tezacaftor/ivacaftor tablet each morning and one ivacaftor tablet each evening, about 12 hours apart. The morning tablet contains tezacaftor 100 mg and ivacaftor 150 mg. The evening tablet contains ivacaftor 150 mg. Your provider may adjust the dose if you have liver impairment or take certain medications.
Take Symdeko with fat-containing food to improve absorption, and swallow the tablets whole. It is a tablet, not an injection or infusion. Always use it exactly as your healthcare provider directs.
Symdeko is long-term, ongoing therapy, typically lifelong in eligible people with cystic fibrosis. It helps maintain CFTR function and slow disease progression. Do not stop taking it without first talking to your healthcare provider.
Store Symdeko at room temperature, away from moisture and heat.
Your healthcare provider will regularly monitor liver function tests and your overall response to treatment. Children may also need eye (ophthalmologic) exams. Report any side effects or unusual symptoms to your healthcare provider.
BENEFITS AND SAFETY
Symdeko (tezacaftor/ivacaftor) treats the underlying cause of cystic fibrosis in eligible people by improving the function of the defective CFTR protein. This may help improve lung function and breathing, and may decrease pulmonary flare-ups and hospitalizations. In people with CFLD, treating the CFTR defect may also support liver health, although Symdeko is not specifically approved for liver disease. Benefits vary from person to person. Symdeko works best as part of routine CF care, with ongoing monitoring such as Liver Function Tests (LFTs).
As with any medication, Symdeko may cause side effects. Elevated liver enzymes can occur, so your healthcare provider will check your liver function during treatment and assess whether Symdeko remains a suitable option for you.
BENEFITS
Symdeko improves the function of the defective CFTR protein, which is the underlying problem in cystic fibrosis in eligible people. This is called CFTR modulation. It is the basis for the other benefits listed here.
Symdeko helps improve breathing and respiratory health. This matters because lung (pulmonary) problems are a main part of cystic fibrosis for many people.
Symdeko may decrease pulmonary flare-ups, also called exacerbations, and hospitalizations. Not everyone will see this benefit, and results vary from person to person.
Symdeko treats the underlying cause of cystic fibrosis in eligible people, rather than only the symptoms. It is used as long-term therapy, typically lifelong, to maintain CFTR function and slow disease progression. Do not stop taking it without first talking to your healthcare provider.
Your healthcare provider will discuss the potential benefits and risks before treatment. Regular liver function tests help catch elevated liver enzymes early. Report any side effects or unusual symptoms to your care team.
SUPPORTING YOUR RESULTS
Lifestyle habits are an important part of care alongside Symdeko. Your care team advises keeping up with airway clearance therapy, eating well, avoiding smoke exposure, staying hydrated, and following routine CF care.
Taking Symdeko with fat-containing food also helps your body absorb it.
Areas that may support treatment:
common questions
Symdeko may be prescribed if you have cystic fibrosis with an eligible CFTR mutation. Genetic testing confirms whether you qualify for CFTR modulator therapy. Your provider may also consider it if you need long-term treatment to improve CFTR protein function or have lung manifestations of cystic fibrosis. Your medical history, liver function, and other medications also matter. Only a qualified healthcare professional can decide whether Symdeko is right for you, so talk with your care team about your genetic test results.
Take one tezacaftor/ivacaftor tablet each morning and one ivacaftor tablet each evening, about 12 hours apart. Take both with fat-containing food to improve absorption, and swallow the tablets whole. The morning tablet contains tezacaftor 100 mg and ivacaftor 150 mg. The evening tablet contains ivacaftor 150 mg. Your provider may adjust the dose if you have liver impairment or take certain medications, so always follow your provider's directions.
Common side effects of Symdeko include headache, nasal congestion, nausea, dizziness, and elevated liver enzymes. Because liver enzymes can rise, regular liver function tests are recommended during treatment, and children may also need eye exams. Report any side effects or unusual symptoms to your healthcare provider. Your provider can explain the potential benefits and risks before you start and decide whether Symdeko remains a suitable option for you.
Symdeko helps improve breathing and respiratory health in eligible people with cystic fibrosis. It improves the function of the defective CFTR protein and may decrease pulmonary flare-ups and hospitalizations. Results vary from person to person, and Symdeko works best alongside routine CF care, such as airway clearance therapy. Ask your healthcare provider what to expect based on your own health and treatment goals.
No. Symdeko is not specifically approved to treat liver disease. It treats cystic fibrosis in people with eligible CFTR mutations. In people with cystic fibrosis–associated liver disease (CFLD), treating the underlying CFTR defect may also support liver health. Symdeko does not replace liver care, and your provider will keep monitoring your liver function with regular tests. Ask your care team how Symdeko fits into your liver care plan.
Symdeko combines tezacaftor and ivacaftor, while Orkambi combines lumacaftor and ivacaftor. Both are CFTR modulators for cystic fibrosis, but eligibility differs. Symdeko is for eligible CFTR mutations confirmed by genetic testing. Orkambi is for people with two copies of the F508del mutation. Dosing also differs: Symdeko uses a morning and an evening tablet, while Orkambi is typically two tablets every 12 hours. Ask your provider which medicine fits your genetic test results.
No, not without talking to your healthcare provider first. Symdeko is long-term, ongoing therapy, typically lifelong in eligible people with cystic fibrosis. It helps maintain CFTR function and slow disease progression. If side effects bother you or you have concerns about treatment, tell your provider. Together you can decide whether any change to your treatment is appropriate.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
